|VCAM1||CD2||B-lymphocyte stimulator protein (BLyS)|
At present, for the immunotherapy of rheumatoid arthritis, five different TNF inhibitors, one inhibitor of IL‑1 and of IL‑6, as well as one B- and one T-lymphocyte-targeting molecules are available.
A 360° review of immunotherapy for autoimmune diseases of type 1 diabetes are listed, including antigen-specific trials, anti-inflammatory trials, T/B cell trials and cytokine trials.
Despite the several therapies proposed to treat multiple sclerosis, none of them has shown to be completely effective. In every case, a strong inflammatory response, TLR-mediated, appears to contribute to this autoimmune disease. The TLR agonist and antagonist may solve this problem.
Targeted immunotherapy, especially for cytokines, has acted as a important role in the treatment of psoriasis
Systemic lupus erythematosus (SLE) is an autoimmune syndrome that poses significant challenges in diagnosis and treatment. Novel immunotherapies with different mechanisms of action that are currently under development include biologic agents targeting co-stimulatory molecules, cytokines or their receptors and signaling molecules and B cells, cell-based therapy and peptide therapy.